Delving into the Latest Updates on TQB-3617 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [1]

Target

BET

Action

inhibitors

Mechanism

BET inhibitors(Bromodomain and extra terminal domain protein inhibitors)

Therapeutic Areas

Hemic and Lymphatic DiseasesOther DiseasesNeoplasms

Active Indication

MyelofibrosisAdvanced cancer

Inactive Indication-

Originator Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active Organization

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Inactive Organization-

License Organization

Centaurus Biopharma Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the effectiveness of TQ05105 tablets combined with TQB3617 capsules in the treatment of moderate- and high-risk myelofibrosis (MF). Secondary objective: To evaluate the safety and improvement of related symptoms of TQ05105 tablets combined with TQB3617 capsules in the treatment of moderate- and high-risk MF subjects.

Start Date21 Nov 2023

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT05834543

/ RecruitingPhase 1/2

Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined chemotherapy.
The primary efficacy outcomes are progression free survival (PFS) and objective response rate (ORR).

Start Date26 May 2023

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with TQB-3617

Login to view more data

100 Translational Medicine associated with TQB-3617

Login to view more data

100 Patents (Medical) associated with TQB-3617

Login to view more data

100 Deals associated with TQB-3617

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelofibrosis	Phase 2	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	21 Nov 2023
Advanced cancer	Phase 1	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	21 Dec 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05110807 (ASCO2024)	Phase 1	Recurrent Hematologic Malignancy	36	TQB3617 0.05mg	(lutbdznews) = zebzyvruin teyhyftgmi (iqzabjvtfc )	Positive	24 May 2024
				TQB3617 0.1mg	refwesuzoq(fcmdhoiudu) = kokgjzkliv cfhuadacar (wpiwoxjoit ) View more